Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

Despite the development of new antineoplastic agents for the treatment of colorectal cancer (CRC), oxaliplatin and fluoropyrimidines remain the most commonly employed drugs for the treatment of both early and advanced disease. Intrinsic or acquired resistance is, however, an important limitation to...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Perez, Marco, Lucena-Cacace, Antonio, Marín-Gómez, Luis Miguel, Padillo-Ruiz, Javier, Robles-Frias, Maria Jose, Saez, Carmen, Garcia-Carbonero, Rocio, Carnero, Amancio
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2016
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078079/
https://ncbi.nlm.nih.gov/pubmed/27105527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8880
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים